yahoo_financeOriginal article
BioMarin Says 5-Year Data Shows Durable Efficacy of Pombiliti Plus Opfolda in Pompe Disease
Data ReadoutpositivePombiliti Plus OpfoldaPositive
AI Analysis
Summary
BioMarin announced 5-year follow-up data demonstrating durable efficacy for Pombiliti Plus Opfolda in Pompe Disease patients, supporting the long-term benefit profile of the combination treatment.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
5-year data shows durable efficacy
Importance:6/10
Sentiment:
0.70
long-term efficacyPompe Diseasecombination therapyclinical data
Related Companies
Read the original article
Published by yahoo_finance on October 2, 2026 3:56 PM